Treatment with long acting repeatable bromocriptine (Parlodel-LAR *) in patients with macroprolactinomas: Long-term study in 29 patients

Journal of Endocrinological Investigation

Volumn 19, Issue 7, 1996, Pages 472-479

  Jamrozik, S I ^a   Bennet, A P ^a   James Deidier, A ^b   Tremollieres, F ^a   Saint Martin, F ^a   Dumoulin, S ^a   Valat Coustols, M ^a   De Glisezinski, I ^a   Tremoulet, M ^a   Manelfe, C ^a   Louvet, J P ^a  

^a CHU PURPAN   (France)

^b Laboratoires Sandoz   (France)

Author keywords

Bromocriptine; Macroadenoma; Pituitary; Prolactin; Prolactinoma

Indexed keywords

BROMOCRIPTINE; HORMONE ANTAGONIST; PROLACTIN;

ADULT; ARTICLE; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS TUMOR; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METABOLISM; PHYSIOLOGY; PROLACTINOMA; RADIOGRAPHY; TIME; VISUAL FIELD;

ADULT; BROMOCRIPTINE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HORMONE ANTAGONISTS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VISUAL FIELDS;

EID: 0030179967     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349893     Document Type: Article

References (24)

1. Bevan J., Webster J., Burke C., Scanlon M. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13:220, 1992.
2. Ciccarelli E., Miola C., Grottoli S., Lancranjan I., Camanni F. Chronic treatment with long-acting injectable repeatable bromocriptine and comparison with oral bromocriptine in hyperprolactinemic patients. J. Endocrinol. Invest., 14(Suppl. 1): abstract OC 31, 1991.
3. Ciccarelli E., Miola C., Grottoli S., Avataneo T., Lancranjan I., Camanni F. Long-term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine. J .Clin. Endocrinol. Metab. 76: 484, 1993.
4. Maraschini C., Moro M., Masala A., Toja P., Alagna S., Brunani A., Rovasio P.P., Givanni A., Lancranjan L, Cavagnini F. Chronic treatment with Parlodel-LAR of patients with prolactin-secreting tumours . Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol. (Copenh.) 125: 494, 1991.
5. Haase R., Jaspers C., Schulte H.M., Lancranjan I., Pfingsten H., Orri-Fend M., Reinwein D., Benker G. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up 3 years. Clin. Endocrinol. (Oxf.) 38: 165, 1993.
6. Brue T., Dewailly D., Lancranjan I., Roger P., Louvet J.P, Jaquet P. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Fertil. Steril. 57: 74, 1992.
7. Beckers A., Petrossians P., Abs R., Flandroy P., Stadnik T., de Longueville M., Lancranjan I., Stevenaert A. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J. Clin. Endocrinol. Metab. 75: 275, 1992.
8. Hardy J. Le prolactinome. Aspects chirurgicaux. Neurochirurgie 27 (Suppl. 1): 41, 1981.
9. Van Schaardenburg D., Van Seters A.P. Bromocriptine therapy for non functioning adenomas. Clin Endocrinol. (Oxf.) 30: 475, 1989.
10. Van't Verlaat J., Lancranjan I., Hendricks M., Croughs R. Primary treatment of macroprolactinomas with Parlodel LAR*. Acta Endocrinol. (Copenh.) 119: 51, 1988.
11. Kocijancic A., Prezelj J., Vrohovec I., Lancranjan I. Parlodel LAR* in the treatment of macroprolactinomas. Acta Endocrinol. (Copenh.) 122: 272, 1990.
12. Schettini G., Lombardi G., Merola B., Colao A., Miletto P., Caruso E., Lancranjan I. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR*). Clin. Endocrinol. (Oxf.) 33: 161, 1990.
13. Bronstein M., Musolino C., Monteiro M., Marino R. Treatment of macroprolactinomas with a long-acting parenteral and repeatable new form of bromocriptine. Advances in the Biosciences (Pergamon Press) 69: 313, 1988.
14. Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.
15. Van't Verlaat J.W., Croughs R.J.M., Hendriks M.J., Bosma N.J. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. Can. J. Neurol. Sci. 17: 71, 1990.
16. Liuzzi A., Dallabonzana D., Oppizzi G., Verde G.G., Cozzi R., Chiodini P., Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med. 313: 656, 1985.
17. Van der Lely A., Brownell J., Lamberts S.W.J. The efficacy and tolerability of CV 205-502 (a non-ergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J. Clin. Endocrinol. Metab. 72: 1136, 1991.
18. Kvistborg A., Halse J., Bakke S., Bjoro T., Hansen E., Djoseland O., Brownell J., Jervell J. Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol. (Copenh.) 128: 301, 1993.
19. Vance M. L., Lipper M., Klibanski A., Biller B.M.K., Samaan N.A., Molitch M.E. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamin agonist CV 205-502. Ann. Intern. Med. 112: 668, 1990.
20. Serri O., Beauregard H., Lesage J., Pedneault L., Comtois R., Jilwan N., Somma M., Vachon L., Brownell J. Long term treatment with CV 205-502 in patients with prolactin- secreting pituitary macroadenomas. J. Clin. Endocrinol. Metab. 71: 682, 1990.
21. Ferrari C., Piscitelli G., Crosignani P. Cabergoline: a new drug for the treatment of hyper-prolactinaemia. Hum. Reprod. 10: 1647, 1995.
22. Berezin M., Shimon I., Hadani M. Prolactinoma in 53 men: clinical characterictics and modes of treatment (male prolactinoma). J. Endocrinol. Invest. 18: 436, 1995.
23. Lengyel A.M., Vieira J.G., Mussio W., Lancranjan I., Imamura P. Long-acting injectable Bromocriptine (Parlodel-LAR*) in the chronic treatment of prolactin-secreting macroadenomas. Fertil. Steril. 59: 980, 1993.
24. Ferrari C., Paracchi A., Mattei A.M., de Vincentiis S., d'Alberton A., Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126: 489, 1992.